Press Release – New York, NY – December 2, 2025 – Sichenzia Ross Ference Carmel LLP announced that it represented FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, in its recently closed $1.5 million registered direct offering (priced at-the-market under Nasdaq rules) of shares of common stock and its concurrent private placement of unregistered warrants to purchase common stock. The unregistered warrants will be exercisable beginning on the effective date of, and subject to, approval by the company’s stockholders of the issuance of the shares of common stock upon exercise of the unregistered warrants.
The SRFC team was led by partners Gregory Sichenzia and Barrett DiPaolo, with associate Karina Maas.
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The H.C. Wainwright team was led by Noam Rubinstein, Michael Mirsky and Ilya Kravets.